{"id":"nilotinib-300-mg","safety":{"commonSideEffects":[{"rate":"37","effect":"Rash"},{"rate":"22","effect":"Pruritus"},{"rate":"24","effect":"Nausea"},{"rate":"27","effect":"Headache"},{"rate":"19","effect":"Fatigue"},{"rate":"18","effect":"Diarrhea"},{"rate":"11","effect":"Vomiting"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Myelosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nilotinib binds to the ATP-binding pocket of BCR-ABL tyrosine kinase, preventing phosphorylation and downstream signaling that drives leukemic cell growth. It is a second-generation BCR-ABL inhibitor with improved potency and selectivity compared to imatinib, and also inhibits other kinases including PDGFR and c-KIT. By blocking these oncogenic kinases, it induces apoptosis and cell cycle arrest in chronic myeloid leukemia cells.","oneSentence":"Nilotinib is a tyrosine kinase inhibitor that selectively blocks BCR-ABL and other kinases to inhibit abnormal cell proliferation in chronic myeloid leukemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:02.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis"},{"name":"Philadelphia chromosome-positive acute lymphoblastic leukemia"}]},"trialDetails":[{"nctId":"NCT04449549","phase":"PHASE2","title":"Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-24","conditions":"Neoplasms","enrollment":82},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT02379416","phase":"PHASE1","title":"Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-04-13","conditions":"Solid Tumors","enrollment":47},{"nctId":"NCT02947893","phase":"PHASE2","title":"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2017-01","conditions":"Alzheimer's Disease","enrollment":37},{"nctId":"NCT05456191","phase":"PHASE3","title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-21","conditions":"Philadelphia Chromosome-Positive Chronic Myeloid Leukemia","enrollment":568},{"nctId":"NCT03874858","phase":"PHASE2","title":"A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-22","conditions":"Chronic Myeloid Leukemia","enrollment":124},{"nctId":"NCT03784014","phase":"PHASE3","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-19","conditions":"Soft Tissue Sarcoma","enrollment":603},{"nctId":"NCT03578367","phase":"PHASE2","title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-22","conditions":"CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic","enrollment":104},{"nctId":"NCT01316250","phase":"NA","title":"Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2010-08","conditions":"Chronic Myelogenous Leukemia","enrollment":13},{"nctId":"NCT02917720","phase":"PHASE2","title":"2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"European LeukemiaNet","startDate":"2016-09","conditions":"Chronic Myeloid Leukemia","enrollment":75},{"nctId":"NCT01784068","phase":"PHASE2","title":"Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-19","conditions":"Chronic Myelogenous Leukemia","enrollment":215},{"nctId":"NCT01698905","phase":"PHASE2","title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-20","conditions":"Chronic Myeloid Leukemia","enrollment":163},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT04838041","phase":"PHASE2","title":"Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-11","conditions":"Chronic Phase Chronic Myelogenous Leukemia","enrollment":51},{"nctId":"NCT06409936","phase":"PHASE2","title":"PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML","status":"RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2025-06-26","conditions":"CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive","enrollment":160},{"nctId":"NCT03906292","phase":"PHASE2","title":"Frontline Asciminib Combination in Chronic Phase CML","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Jena","startDate":"2019-08-19","conditions":"Chronic Myeloid Leukemia","enrollment":125},{"nctId":"NCT05185947","phase":"PHASE2","title":"Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-13","conditions":"Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis","enrollment":19},{"nctId":"NCT01657604","phase":"PHASE3","title":"TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study","status":"COMPLETED","sponsor":"University of Jena","startDate":"2012-08-24","conditions":"Chronic Myeloid Leukemia","enrollment":717},{"nctId":"NCT01810718","phase":"PHASE1","title":"Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD","status":"COMPLETED","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2011-11","conditions":"Chronic Graft Versus Host Disease","enrollment":22},{"nctId":"NCT01025505","phase":"PHASE2","title":"Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2012-06","conditions":"Treatment, Stem Cell Transplantation","enrollment":40},{"nctId":"NCT01774630","phase":"PHASE2","title":"Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2013-04-10","conditions":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":31},{"nctId":"NCT02546674","phase":"PHASE4","title":"Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-02-18","conditions":"Chronic Myeloid Leukemia","enrollment":171},{"nctId":"NCT02353728","phase":"PHASE2","title":"Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2015-01","conditions":"Chronic Myeloid Leukemia","enrollment":16},{"nctId":"NCT00644878","phase":"PHASE2","title":"Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":18},{"nctId":"NCT01743989","phase":"PHASE3","title":"A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04-15","conditions":"Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","enrollment":620},{"nctId":"NCT00980018","phase":"PHASE4","title":"An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Myelogenous Leukemia","enrollment":52},{"nctId":"NCT02973711","phase":"PHASE1, PHASE2","title":"A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2018-01","conditions":"Leukemia, Chronic Myeloid","enrollment":""},{"nctId":"NCT01856283","phase":"PHASE2","title":"Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells","status":"COMPLETED","sponsor":"Niguarda Hospital","startDate":"2013-03","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":87},{"nctId":"NCT01702064","phase":"PHASE1","title":"Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-21","conditions":"Chronic Phase Chronic Myeloid Leukemia","enrollment":11},{"nctId":"NCT00471497","phase":"PHASE3","title":"A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07-31","conditions":"Myelogenous Leukemia, Chronic","enrollment":846},{"nctId":"NCT04578847","phase":"PHASE2","title":"A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2020-01-15","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia","enrollment":100},{"nctId":"NCT01274351","phase":"PHASE2","title":"Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01-25","conditions":"Chronic Myelogenous Leukemia","enrollment":112},{"nctId":"NCT01744665","phase":"PHASE2","title":"A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-12","conditions":"CML","enrollment":59},{"nctId":"NCT02115386","phase":"PHASE3","title":"Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-17","conditions":"Philadelphia Positive (Ph+) Chronic Myeloid Leukemia","enrollment":7},{"nctId":"NCT02174445","phase":"PHASE3","title":"An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years","status":"TERMINATED","sponsor":"Prof. Dr. Nikolas von Bubnoff","startDate":"2014-03","conditions":"Chronic Myeloid Leukemia","enrollment":14},{"nctId":"NCT02611492","phase":"PHASE3","title":"A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04","conditions":"Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia","enrollment":265},{"nctId":"NCT02272777","phase":"PHASE3","title":"A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-07-17","conditions":"Leukemia","enrollment":225},{"nctId":"NCT01294618","phase":"PHASE2","title":"Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-03","conditions":"Chronic Myelogenous Leukemia","enrollment":60},{"nctId":"NCT01871311","phase":"PHASE1","title":"A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2014-05","conditions":"Colorectal Cancer, Head and Neck Cancer","enrollment":15},{"nctId":"NCT03079505","phase":"PHASE3","title":"Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"Hamad Medical Corporation","startDate":"2017-08-03","conditions":"Chronic Myeloid Leukemia - Chronic Phase","enrollment":10},{"nctId":"NCT01866553","phase":"PHASE2","title":"Nilotinib Plus Pegylated Interferon-α2b in CML","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Chronic Myeloid Leukemia","enrollment":20},{"nctId":"NCT01535391","phase":"PHASE3","title":"Nilotinib in PH+, BCR-, ABL+ CML Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2012-01","conditions":"Chronic Myeloid Leukemia","enrollment":109},{"nctId":"NCT02108951","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-07-07","conditions":"Philidelphia Positive Chronic Myeloid Leukaemia","enrollment":20},{"nctId":"NCT03205267","phase":"PHASE2","title":"Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients","status":"UNKNOWN","sponsor":"University of Bonn","startDate":"2016-03","conditions":"Chronic Myelogenous Leukaemia","enrollment":127},{"nctId":"NCT01605981","phase":"PHASE4","title":"Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":""},{"nctId":"NCT01275586","phase":"EARLY_PHASE1","title":"Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas","status":"COMPLETED","sponsor":"Indiana University","startDate":"2011-01","conditions":"Neurofibromatosis, NF1, Neurofibromas","enrollment":6},{"nctId":"NCT02086487","phase":"PHASE4","title":"Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy","status":"TERMINATED","sponsor":"King Abdullah International Medical Research Center","startDate":"2013-03","conditions":"Myeloid Leukemia, Chronic","enrollment":98},{"nctId":"NCT01061177","phase":"PHASE4","title":"Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05","conditions":"CML in Chronic Phase","enrollment":1090},{"nctId":"NCT01254188","phase":"PHASE3","title":"Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Chronic Myeloid Leukemia","enrollment":421},{"nctId":"NCT01227577","phase":"PHASE4","title":"CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":"Chronic Myelogenous Leukemia in Chronic Phase","enrollment":128},{"nctId":"NCT01179737","phase":"PHASE2","title":"Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07","conditions":"Pulmonary Arterial Hypertension","enrollment":23},{"nctId":"NCT01819389","phase":"PHASE3","title":"Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2012-10","conditions":"Leukemia, Myeloid, Chronic, BCR-ABL Positive","enrollment":10},{"nctId":"NCT00441155","phase":"PHASE1","title":"Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Gastrointestinal Stromal Tumors","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tasigna 300 mg"],"phase":"marketed","status":"active","brandName":"Nilotinib 300 mg.","genericName":"Nilotinib 300 mg.","companyName":"King Abdullah International Medical Research Center","companyId":"king-abdullah-international-medical-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nilotinib is a tyrosine kinase inhibitor that selectively blocks BCR-ABL and other kinases to inhibit abnormal cell proliferation in chronic myeloid leukemia. Used for Chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis (BCR-ABL positive), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}